| Gao, Xinghua |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT06587685: A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis |
|
|
| Recruiting | 3 | 472 | RoW | PG-011Gel, PG-011Gel 3%, Vehicle, placebo | Prime Gene Therapeutics Co., Ltd. | Atopic Dermatitis | 12/24 | 01/26 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 2 | 41 | RoW | BDB-001 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 08/23 | 08/23 | | |
NCT04612699: A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis |
|
|
| Active, not recruiting | 2 | 123 | RoW | Jaktinib, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Moderate-to-Severe Plaque Psoriasis | 12/24 | 12/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT06058000: A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 120 | RoW | 1.5% QLM3003, 2% QLM3003, Vehicle (Placebo) | Qilu Pharmaceutical Co., Ltd. | Atopic Dermatitis | 10/24 | 12/24 | | |
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 1/2 | 50 | RoW | BDB-001 Injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 07/23 | 07/23 | | |
SHR-1819-204, NCT06713499: A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis |
|
|
| Not yet recruiting | 1/2 | 36 | RoW | SHR-1819 injection | Guangdong Hengrui Pharmaceutical Co., Ltd | Children and Adolescents With Moderate-to-severe Atopic Dermatitis | 06/25 | 08/25 | | |
NCT06433531: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) |
|
|
| Recruiting | 1 | 10 | RoW | TQH2929 Injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Generalized Pustular Psoriasis | 02/25 | 02/25 | | |
NCT05146895: A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts |
|
|
| Recruiting | N/A | 60 | RoW | Imiquimod treatment, Local Hyperthermia at 44℃ | First Hospital of China Medical University | Human Papilloma Virus | 06/22 | 06/22 | | |
NCT05863273: Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT） |
|
|
| Not yet recruiting | N/A | 360 | RoW | Apremilast | First Hospital of China Medical University, China-Japan Friendship Hospital | Psoriasis | 03/24 | 12/24 | | |
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China |
|
|
| Recruiting | N/A | 130 | RoW | No intervention | Takeda | Hereditary Angioedema (HAE) | 08/25 | 08/25 | | |
